Lymphogranuloma Venereum

What Sets LGV Apart

Same species as ordinary genital chlamydia/trachoma: C. trachomatis. But DIFFERENT SEROVARS: L1, L2, L3 (vs D-K genital serovars). L-serovars: preferentially invade LYMPHATIC TISSUE/regional nodes (not just mucosal epithelium like D-K) — explains entire divergent clinical picture.

Epidemiology

Endemic: Africa, Asia, S. America. Re-emerged in high-income countries: MSM outbreaks, PROCTITIS presentation — real shift from classic genital-ulcer-bubo picture.

Clinical Stages

Primary: small, PAINLESS, often TRANSIENT papule/shallow ulcer, heals quickly (days). Inconspicuous — often UNNOTICED (contrast syphilis chancre — also painless but obvious/persistent).

Secondary (2-6wk after primary): stage that BRINGS patients to care. Presentation by exposure route:

Genital exposure: painful tender INGUINAL/FEMORAL LAD. Both groups involved → “GROOVE SIGN” (inguinal ligament creates groove between swollen node clusters) — near-pathognomonic, minority of cases. Nodes mat, become fluctuant buboes, rupture → MULTIPLE draining sinuses (contrast chancroid’s SINGLE sinus).
Receptive anal exposure (dominant in MSM outbreaks): HEMORRHAGIC PROCTITIS — rectal pain, discharge, bleeding, tenesmus. Mimics IBD — genuine diagnostic pitfall, NOT the “classic” teaching picture.

Tertiary (late, untreated, more women/anal-exposure cases): chronic lymphatic obstruction/fibrosis → genital elephantiasis (lymphedema, “ESTHIOMENE” if vulvar) + rectal strictures. Destructive, disfiguring, hard to reverse — why timely 2° stage treatment matters.

Laboratory Diagnosis

NAAT (C. trachomatis): bubo aspirate/rectal swab/ulcer swab. Standard NAAT does NOT distinguish L-serovars from D-K routinely → positive + compatible clinical picture (significant LAD, groove sign, proctitis, high-risk exposure) = TREATED PRESUMPTIVELY as LGV. Specific genotyping = reference labs/outbreak investigation only.

Serology (CF or micro-IF, HIGH titer): MORE useful here than ordinary chlamydial infection (where serology not useful for acute Dx) — LGV’s invasive lymphatic process = more robust Ab response than superficial D-K mucosal infection.

Treatment

Doxycycline, PROLONGED 3-WEEK course (vs shorter ordinary chlamydial regimens — deeper lymphatic tissue involvement needs longer clearance) = DOC. Fluctuant bubo: needle aspiration (through intact skin, avoid chronic sinus) for symptom relief. I&D avoided (delayed healing, same logic as chancroid). PARTNER TREATMENT essential regardless of symptoms.

What Sets LGV Apart

Lymphogranuloma venereum (LGV) is caused by Chlamydia trachomatis — the identical species responsible for ordinary genital chlamydial infection and trachoma — but behaves as a genuinely different, considerably more invasive disease, and the reason lies entirely in which serovars are involved: LGV is caused specifically by serovars L1, L2, and L3, which are distinguished from the D–K genital serovars by a real, demonstrable difference in tissue tropism and invasiveness — L-serovar strains preferentially invade and replicate within lymphatic tissue and regional lymph nodes rather than staying confined to mucosal epithelial cells the way D–K serovars do, and this single biological difference explains the entire divergent clinical picture that follows.

Epidemiology

LGV is endemic in parts of Africa, Asia, and South America, and, while historically uncommon in high-income countries, has re-emerged as a genuinely significant cause of outbreaks among men who have sex with men (MSM), particularly presenting as proctitis, in several countries over the past two decades — a real shift in the disease’s typical clinical presentation and epidemiological profile from its classically described genital-ulcer-and-bubo picture.

Clinical Stages

LGV progresses through three recognizable stages, and — unlike syphilis’s similarly staged natural history — the first stage is often so mild it goes entirely unnoticed, which matters directly for diagnosis, since patients frequently present only once the disease has already reached its more dramatic second stage:

Primary stage: a small, painless, often transient papule or shallow ulcer at the inoculation site, healing quickly within days — genuinely inconspicuous enough that most patients never notice or recall it, in real contrast to syphilis’s primary chancre, which, while also painless, is a far more obvious, persistent lesion.

Secondary stage (occurring 2–6 weeks after the primary lesion, reflecting the organism’s lymphatic spread from the healed primary site): this is the stage that actually brings most patients to care, and its presentation differs by anatomical route of exposure. Following genital exposure, it produces painful, tender inguinal and/or femoral lymphadenopathy — when both nodal groups are involved simultaneously, the intervening inguinal ligament creates a groove between the swollen node clusters, the “groove sign” (a genuinely distinctive, near-pathognomonic physical finding when present, though seen in only a minority of cases). Involved nodes can mat together, become fluctuant buboes, and rupture to form multiple draining sinus tracts — a directly useful point of contrast with chancroid’s bubo, which forms only a single sinus if it ruptures. Following receptive anal exposure (increasingly the dominant presentation in the MSM outbreaks described above), the disease instead presents as haemorrhagic proctitis — rectal pain, discharge, bleeding, tenesmus — which can be clinically difficult to distinguish from inflammatory bowel disease, and, is a genuine, recognized diagnostic pitfall worth naming explicitly, given that proctitis is not the “classic” teaching-picture presentation most students first learn.

Tertiary stage (a late, chronic complication in untreated disease, more often described in women and in receptive anal-exposure cases): chronic lymphatic obstruction and fibrosis from longstanding, poorly controlled inflammation produces genital elephantiasis (lymphoedema, sometimes called esthiomene when affecting the vulva specifically) and rectal strictures — genuinely destructive, disfiguring, and difficult-to-reverse complications that are exactly why timely diagnosis and treatment at the secondary stage matters so much.

Laboratory Diagnosis

NAAT for C. trachomatis, performed on a bubo aspirate, rectal swab, or ulcer swab as clinically indicated, confirms the presence of the organism — but standard clinical NAAT testing does not routinely distinguish LGV (L1–L3) serovars from the ordinary genital D–K serovars, so a positive C. trachomatis NAAT in a patient with a compatible clinical picture (significant lymphadenopathy, groove sign, or proctitis in a high-risk exposure context) is generally treated presumptively as LGV, with specific serovar/genotyping reserved for reference laboratories and epidemiological/outbreak investigation rather than routine individual patient management. Serology (complement fixation or micro-immunofluorescence, checking for a high titre) has more practical diagnostic value here than in ordinary chlamydial genital infection (where serology is not useful for acute diagnosis, as covered under Non-gonococcal Urethritis), since LGV’s more invasive, systemic-lymphatic disease process provokes a more robust and diagnostically meaningful antibody response than superficial mucosal D–K infection does.

Treatment

Doxycycline, given for a prolonged three-week course (in real contrast to the shorter regimens used for ordinary chlamydial genital infection, reflecting LGV’s deeper, lymphatic tissue involvement and the longer time needed to clear infection from that compartment) is the treatment of choice. Fluctuant buboes may need needle aspiration for symptomatic relief (through intact skin, to avoid creating a chronic sinus tract), though incision and drainage is generally avoided for the same delayed-healing reasons described under chancroid. As with every other STI in this section, partner treatment is essential regardless of the partner’s symptom status.